Literature DB >> 15365215

Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.

Ruth Gross-Isseroff1, Rivka Cohen, Yehuda Sasson, Hillary Voet, Joseph Zohar.   

Abstract

We have conducted a pharmacological challenge experiment in 10 medication-free obsessive compulsive (OC) disorder (OCD) patients. We used a placebo-controlled paradigm for m-chlorophenylpiperazine (mCPP) and sumatriptan challenges. Endocrine, physiological and behavioral variables were assessed at baseline and over a 3-hour period after the challenge. Both cortisol and prolactin were significantly elevated in OCD patients following mCPP administration. Both mCPP and sumatriptan caused significant OC symptom exacerbation with the response to sumatriptan being more robust. We conclude that the 5-HT(1Dbeta) receptor may play a role in the pathophysiology of OCD. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365215     DOI: 10.1159/000079970

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  23 in total

1.  Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.

Authors:  Silvia Victoria Navarro; Valeria Gutiérrez-Ferre; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2014-08-26       Impact factor: 4.530

3.  OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding.

Authors:  Christopher Pittenger; Thomas G Adams; Jean-Dominique Gallezot; Michael J Crowley; Nabeel Nabulsi; Hong Gao; Stephen A Kichuk; Ryan Simpson; Eileen Billingslea; Jonas Hannestad; Michael Bloch; Linda Mayes; Zubin Bhagwagar; Richard E Carson
Journal:  J Affect Disord       Date:  2016-02-09       Impact factor: 4.839

4.  Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.

Authors:  Nancy A Shanahan; Lady P Velez; Virginia L Masten; Stephanie C Dulawa
Journal:  Biol Psychiatry       Date:  2011-09-13       Impact factor: 13.382

5.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

Review 6.  Compulsive features in behavioural addictions: the case of pathological gambling.

Authors:  Nady el-Guebaly; Tanya Mudry; Joseph Zohar; Hermano Tavares; Marc N Potenza
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

Review 7.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

Review 8.  The genetic studies of obsessive-compulsive disorder and its future directions.

Authors:  Se Joo Kim; Chan-Hyung Kim
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

9.  Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation.

Authors:  Nancy S Woehrle; Stephanie J Klenotich; Naseem Jamnia; Emily V Ho; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2013-02-03       Impact factor: 4.530

10.  Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).

Authors:  Mark C Tucci; Anna Dvorkin-Gheva; Dawn Graham; Sean Amodeo; Paul Cheon; Ashley Kirk; John Peel; Leena Taji; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2013-01-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.